Abstracts tagged "quality of life"

Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Vibeke Strand¹, Puja Khanna², Alan Kivitz³, Nana Kragh⁴, Aletta Falk⁵, Rehan Azeem⁶, Hugues Santin-Janin⁷ and Herbert Baraf⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Michigan, Ann Arbor, MI, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Sobi, Stockholm, Sweden, ⁶Sobi Inc., Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…
Abstract Number: 0794 • ACR Convergence 2024
Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup
Shreena Kamlesh Gandhi¹, Sofia Pedro², Brian Walitt³, Winfried Häuser⁴, Robert Katz⁵ and Kaleb Michaud⁶, ¹KU School of Medicine, Wichita, Wichita, KS, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³NIH, Bethesda, MD, ⁴Klinikum Saarbrücken Germany, Munich, Germany, ⁵Rush University Medical Center, Chicago, IL, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Disability benefits are crucial for individuals unable to work due to debilitating medical conditions, commonly facilitated through programs like Social Security Disability Insurance (SSD)…
Abstract Number: 1480 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Victoria Navarro Compán¹, Maureen Dubreuil², Karl Gaffney³, Jonathan Kay⁴, Christine de la Loge⁵, Ute Massow⁶, Vanessa Taieb⁷, Thomas Vaux⁸ and Atul Deodhar⁹, ¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ³Health Care - NHS, Norwich, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Slough, United Kingdom, ⁹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…
Abstract Number: 2368 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Philip Mease¹, William Tillett², Maarten de Wit³, Laure Gossec⁴, M. Elaine Husni⁵, Fabian Proft⁶, Barbara Ink⁷, Rajan Bajracharya⁷, Jason Coarse⁸, Jérémy Lambert⁹, Laura Coates¹⁰ and Alice Gottlieb¹¹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁴Sorbonne Université, Paris, France, ⁵Cleveland Clinic, Cleveland, OH, ⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Morrisville, NC, ⁹UCB Pharma, Colombes, France, ¹⁰University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: PsA significantly impacts patients' quality of life due to functional limitations, pain, and fatigue.1 Sustained relief from pain and fatigue are therefore important aims…
Abstract Number: 0359 • ACR Convergence 2024
SpA Disk©: A New Tool to Monitor the QoL of Spondyloarthritis Patients
Roba Ghossan¹, OLIVIER FOGEL², Cécile Gaujoux-Viala³, anthony SABER⁴, Cedric Lukas⁵ and Corinne MICELI⁶, and SpA Disk Group, ¹COCHIN HOSPITAL, PARIS, France, ²AP-HP, Paris, France, ³CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ⁴Sorbonne Paris Nord Université, Paris, France, ⁵Rheumatology department, CHU Montpellier, Montpellier, France, ⁶Université de Paris Cité, APHP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) significantly affects patients' quality of life (QoL). Current tools in routine medical practice primarily focus on assessing disease activity, neglecting the broader…
Abstract Number: 0983 • ACR Convergence 2024
Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey
Aleksander Lenert¹, Mary E. Charlton¹, Jacob J. Oleson¹, Robyn Domsic² and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: General well-being, an individual’s subjective assessment of their life overall, may be impacted by arthritis. It is unclear if adults with arthritis have lower…
Abstract Number: 1510 • ACR Convergence 2024
Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Nidia Meras⁸, Cintia Otaduy⁹, Elisa Novatti¹⁰, Valeria Arturi¹¹, Erika S. Palacios Santillan⁷, Boris Kisluk¹², Luciana González Lucero¹³, Eduardo Kerzberg¹⁴, Nicolás Pérez¹⁵, Cecilia Pisoni¹⁶, Paola Pirruccio¹⁷, María E. Crespo¹⁸, Ana Carolina Montandon¹⁹, Andrese A. Gasparin²⁰, Angela Duarte²¹, Laissa C. Alves Alvino²², Eloisa Bonfa²³, Emily Figuereido Neves²⁴, Lucas Victoria De Oliveira Martins²⁵, Iris Guerra²⁶, Milena Mimica Davet²⁷, Lizeth De La Hoz Rueda²⁸, Andrés Cadena Bonfanti²⁸, Roberth Rivera²⁹, Paola Coral Alvarado³⁰, John Fredy Jaramillo³¹, José Martínez³², Mario Moreno³³, Reyna E. Sánchez Briones³⁴, Mario Pérez Cristóbal³⁵, Eduardo Martin Nares³⁶, Yaneli Juárez-Vicuña³⁷, Yelitza González Bello³⁸, Octavio González³⁹, Leonardo R. Aguilar Rivera⁴⁰, Margarita Duarte⁴¹, Patricia Langjarth⁴², Wilkerson Pérez Medina⁴¹, Armando Calvo⁴³, Teresandris Polanco⁴⁴, Carina Pizzarossa⁴⁵, Gonzalo Silveira⁴⁶, Cristina Reategui⁴⁷, Graciela Alarcon⁴⁸, Urbano Sbarigia⁴⁹, Federico Zazzetti⁵⁰, Ashley Orillion⁵¹, Guillermo Pons-Estel⁵² and Bernardo Pons-Estel⁵², ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Córdoba, Córdoba, Spain, ⁹Hospital Córdoba, Cordoba, Spain, ¹⁰Hospital Privado Universitario de Córdoba, Córdoba, Spain, ¹¹Hospital HIGA San Martín, La Plata, Argentina, ¹²Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ¹³Hospital Padilla, Tucumán, Argentina, ¹⁴Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹⁵Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁶CEMIC, Buenos Aires, Argentina, ¹⁷Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, ¹⁸Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ²⁰Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²¹Universidad Federal de Pernambuco, Pernambuco, Brazil, ²²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁴Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ²⁸Universidad Simon Bolivar, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³⁷Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, CDMX, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, Mexico, ⁴⁰Servicio de Reumatología (CEAR). Hospital Universitario "Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico, ⁴¹Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Cayetano Heredia, San Martin de Porres, Peru, ⁴⁴Hospital Docente Padre Billini, Santo Domingo, Dominica, ⁴⁵Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁶Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁷Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁸The University of Alabama at Birmingham, Birmingham, AL, ⁴⁹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵⁰Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵¹Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: To evaluate health-related quality of life (HRQoL) in patients with active lupus nephritis (LN) at baseline and 12 months after treatment in relationship to…
Abstract Number: 2370 • ACR Convergence 2024
Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
Daniella Faden¹, lillian Xie², Caroline Stone¹, Lais Lopes Almeida Gomes¹, Ahmed Eldaboush¹, Cristina Ricco², Rui Feng² and Victoria Werth³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Regulatory guidance on endpoint measures for disease activity in cutaneous lupus erythematosus (CLE) patients is essential to improve therapies. CLE profoundly impacts quality of…
Abstract Number: 0385 • ACR Convergence 2024
Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis
sheila Angeles-Han¹, Jordi Anton², Amra Adrovic³, Patricia Costa Reis⁴, Joke De Boer⁵, Séverine Guillaume-Czitrom⁶, Theresa Hennard⁷, Marija Jelusic⁸, Ozgur Kasapcopur⁹, Ilaria Maccora¹⁰, Hana Malcova¹¹, Joseph McDonald¹², Najima Mwase¹³, Gabriele Simonini¹⁴, Waheba Slamang¹⁵, Derrik du Toit¹⁶, Hendrike van Vollenhoven¹⁶ and Ivan Foeldvari¹⁷, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ³Deparment of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Hospital de Santa Maria, Lisbon, Portugal, ⁵Department of ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospital of Bicetre, Kremlin-Bicêtre, France, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ¹⁰?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ¹¹FN Motol, Praha, Czech Republic, ¹²University of Chicago, Chicago, IL, ¹³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁵University of Cape Town, Department of Child and Adolescent Health, Cape Town, South Africa, ¹⁶Red Cross Children’s Hospital, Cape Town, South Africa, ¹⁷Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary…
Abstract Number: 1036 • ACR Convergence 2024
A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care
Rosemary Gedert¹, Danielle Ochocki¹, Neda Kortam¹, Suiyuan Huang¹, Vivek Nagaraja², Katherine Chakrabarti¹, Julia Ford¹, Martin Garber¹, Jiha Lee¹, Vladimir Ognenovski¹, David Roofeh³, David Cella⁴ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Rutgers-RWJ Medical School, New Brunswick, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: Utilizing Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaires can enhance clinical care by measuring longitudinal changes in symptom severity as reported by the patient.…
Abstract Number: 1633 • ACR Convergence 2024
Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients
Koichi Sugihara¹, Risa Wakiya², Hiromi Shimada², Taichi Miyagi², Yusuke Ushio², Rina Mino², Mao Mizusaki³, Hayamasa yamaguchi³, Naoto Manabe³, Shusaku Nakashima² and Hiroaki dobashi², ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, ²Kagawa University, Miki-cho, Kita-gun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Arthritis associated with Behcet's disease (BD) has been reported to be related to patients' quality of life and associated with skin and mucosal lesions.…
Abstract Number: 2403 • ACR Convergence 2024
Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
Fernando A Oliveira¹, Fabiana Moura², Ana Flávia Dias³, Claudia Santoro³, Fernando Pereira², Rosa Telles² and Cristina Lanna², ¹Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ²Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ³Grupo Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: Body image of systemic lupus erythematosus (SLE) patients is affected by the mucocutaneous manifestations and its scars, in particular related to discoid lupus. The…
Abstract Number: 0394 • ACR Convergence 2024
Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective
Francesco Baldo¹, Luciana Peixoto², Remco Erkens³, Greta Rogani³, Claudia Bracaglia⁴, Dirk Foell⁵, Marco Gattorno⁶, Marija Jelusic⁷, Sebastiaan Vastert³, Rashmi Sinha² and Francesca Minoia⁸, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Systemic JIA Foundation, Cincinnati, OH, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵University Hospital Muenster, Muenster, Germany, ⁶IRCCS Giannina Gaslini, Genoa, Italy, ⁷University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
Abstract Number: 1048 • ACR Convergence 2024
Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus
Karina Palomo-Arnaud¹, Gabriel Figueroa-Parra², Angel Kevin Garza-Elizondo¹, Margarita Isabel Alarcon Jarquin³, Jesus Cardenas-de la Garza⁴, Dionicio Galarza-Delgado⁵ and Janett Riega Torres², ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Oral manifestations, especially periodontitis and tooth loss, are highly prevalent in patients with rheumatic diseases. Sjogren’s syndrome (SS), rheumatoid arthritis (RA), and systemic lupus…
Abstract Number: 1675 • ACR Convergence 2024
Extended Validation of the IgG4-Related Disease Symptom Severity Index (SSI)
Isha Jha¹, Grace McMahon¹, Guy Katz¹, Shruthi Srivatsan¹, Caleb Bolden¹, Ana Fernandes¹, Cory Perugino¹, John Stone² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital , Harvard Medical School, Concord, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: The Symptom Severity Index (SSI) is a patient-reported outcome measure (PROM) developed for IgG4-related disease (IgG4-RD). The SSI assesses symptoms of IgG4-RD and the…

1
2
3
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].